The impact of decreased SIRT1 levels on pediatric primary hypertension and left ventricular hypertrophy: a case-control study
Wang Y., Lin Y., Wang H., Li Y., Shen C., Shi L.
Prospective Study with a reported sample of 126, published in BMC Pediatr (2025) — summary generated from the PubMed abstract.
Early human evidence such as case series or small samples is exploring possible benefits.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Prospective Study
- Journal
- BMC Pediatr (2025)
- Reported sample size
- 126
- Source database
- Europe PMC
- PMID
- 40307735
- PMCID
- PMC12042379
- DOI
- 10.1186/s12887-025-05671-z
- Citations
- 1
Abstract (original English)
Background Decreased SIRT1 exhibits a correlation with a range of cardiovascular diseases. However, the changes in serum SIRT1 levels in pediatric primary hypertension have not been reported. This study aimed to investigate serum SIRT1 levels in pediatric primary hypertension and explore its association with left ventricular hypertrophy in the context of hypertension. Methods 126 participants were recruited and categorized into the hypertensive group and the control group. Serum SIRT1 levels were comparatively investigated. Spearman correlation was utilized to establish an association between SIRT1 and blood pressure. Additionally, SIRT1 levels were comparative analyzed between the patients with and without left ventricular hypertrophy. Results The case group had markedly decreased SIRT1 levels than the control group (p Conclusions Serum SIRT1 levels were significantly lower in pediatric primary hypertension patients and were negatively correlated with blood pressure. Patients with left ventricular hypertrophy had significantly lower serum SIRT1 levels, and decreased serum SIRT1 was an independent risk factor for left ventricular hypertrophy.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Early human evidence such as case series or small samples is exploring possible benefits.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.